Esophagus

A newly diagnosed patient with dense eosinophilic esophagitis and a heavy atopic history raises a genuine sequencing question the 2025 ACG guideline doesn't fully close: does her atopic burden justify starting on dupilumab, or does the stepwise pathway still call for a documented PPI trial first.

LIBERTY-TREET, the trial behind dupilumab's EoE approval, excluded patients with an impassable esophageal stricture — leaving a real, currently unanswered question for exactly the fibrostenotic patients most likely to want the drug.

Three legitimate first-line options for newly diagnosed EoE — a PPI trial, swallowed topical steroid, and the six-food elimination diet — carry genuinely comparable efficacy, which makes this less a clinical-evidence question and more a question of what this particular patient can actually sustain.

At LA Grade C/D severity, vonoprazan's own healing-rate data pulls ahead of standard-dose PPI therapy in a way it doesn't at milder grades — a real question of whether to reach for it now or start where the guidelines have started for decades.

Confirmed non-erosive reflux disease that hasn't responded to a properly optimized PPI raises a genuine add-on question — baclofen, which targets the transient relaxations actually driving her reflux events, against a simpler alginate barrier her own pH-impedance data may not fully support.

Chronic throat-clearing and hoarseness with a laryngoscopy read as suggestive of reflux sit at the center of a real, still-unsettled controversy: multiple placebo-controlled trials have failed to show PPI therapy clearly outperforms placebo for these symptoms, yet empiric trials remain common clinical practice.

A patient already on PPI therapy for confirmed non-dysplastic Barrett's esophagus asks a genuinely reasonable question after reading about it himself: does adding aspirin actually lower his risk of progression, or is the real evidence behind that idea weaker than it's often made to sound.

Confirmed, pathologist-reviewed low-grade dysplasia in Barrett's esophagus is a real fork in real practice — endoscopic ablation lowers progression risk in trial data, but continued surveillance on optimized medical therapy remains a legitimate, guideline-recognized alternative, and the choice here turns on how much weight to give one pathologist's read.

With definitive therapy ruled out by severe cardiopulmonary disease, achalasia management for this patient comes down to two genuinely different pharmacologic bridges — botulinum toxin injected directly at the lower esophageal sphincter, or oral smooth-muscle relaxants that work systemically but never as durably.

Manometry-confirmed hypercontractile esophagus leaves the team choosing among three real options — a calcium channel blocker, a PDE-5 inhibitor borrowed from an entirely different indication, and endoscopic botulinum toxin — none backed by strong trial-level evidence, all resting on genuinely differing mechanistic logic.

Active variceal bleeding in a cirrhotic patient turns on two decisions that have to be made before endoscopy, not after it: which vasoactive agent to start, and whether antibiotic prophylaxis can wait for the scope or has to start now.

A confirmed second-degree caustic esophageal injury reopens a genuinely old, still-unsettled question: does adding corticosteroids to standard supportive care actually reduce stricture formation, or does the evidence behind that practice not hold up as well as the tradition does.

New odynophagia in an immunocompromised patient with visible oral thrush is classic enough to treat empirically by most standard practice — but a genuine minority of these presentations turn out to be something else entirely, and the cost of being wrong is a real part of the argument.

Confirmed doxycycline-induced esophageal injury in a patient who has a real, ongoing clinical need for the drug turns the usual first instinct — stop the offending agent — into a genuine choice between administration modification and drug substitution.

Severe esophageal hypomotility from systemic sclerosis has already outpaced what a standard PPI dose can protect against, raising a genuine question about how aggressively to layer acid suppression and prokinetic therapy on a gut whose underlying motor problem no drug in either class actually reverses.

A patient with an acute food bolus stuck in his chest, waiting for the endoscopy team, raises a familiar emergency-department question with a genuinely modest evidence base: does IV glucagon actually help often enough to justify trying it, or does it mostly just delay what endoscopy will do anyway.

New reflux symptoms that began within weeks of starting a GLP-1 receptor agonist raise a real and increasingly common question, given how widely this drug class is now used: treat the reflux directly, or address the delayed gastric emptying actually driving it.

A third dilation for the same recurring stricture, on top of already-optimized acid suppression, raises a real add-on question: does injecting corticosteroid directly into the stricture at the time of dilation meaningfully extend the interval before it narrows again.

Months of cough with no clear pulmonary or allergic explanation land on reflux as a plausible cause — but the randomized evidence for empiric PPI therapy specifically for chronic cough is nearly as mixed as it is for laryngopharyngeal reflux, and this patient's own denial of typical reflux symptoms adds a real, separate wrinkle.

A negative cardiac workup for recurring chest pain shifts the question toward the esophagus — and here the actual disagreement is whether an empiric PPI trial is a reasonable next step or whether it risks anchoring on reflux before ruling out the motility disorders that produce a genuinely similar presentation.

With high-grade dysplasia confirmed and endoscopic ablation no longer a real point of disagreement, the actual question left on the table is whether to add aspirin to high-dose PPI therapy around the ablation itself — the same chemoprevention question as non-dysplastic and low-grade Barrett's, but at meaningfully higher stakes.

Biopsy-confirmed HSV esophagitis in a patient on maintenance immunosuppression after a kidney transplant raises two real, connected questions: whether to start with intravenous or oral antiviral therapy, and how to decide when a course this consequential is actually long enough to stop. ---